Johnson Investment Counsel Inc. Has $2.46 Million Position in Hill-Rom Holdings, Inc. (NYSE:HRC)

Johnson Investment Counsel Inc. cut its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 1.1% during the second quarter, Holdings Channel reports. The fund owned 21,638 shares of the medical technology company’s stock after selling 230 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Hill-Rom were worth $2,458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of HRC. Ifrah Financial Services Inc. lifted its position in shares of Hill-Rom by 3.4% during the 2nd quarter. Ifrah Financial Services Inc. now owns 2,300 shares of the medical technology company’s stock worth $261,000 after buying an additional 76 shares during the last quarter. Advisor Group Holdings Inc. increased its stake in shares of Hill-Rom by 1.5% in the second quarter. Advisor Group Holdings Inc. now owns 6,135 shares of the medical technology company’s stock valued at $698,000 after buying an additional 93 shares during the period. Bedel Financial Consulting Inc. increased its stake in shares of Hill-Rom by 43.0% in the second quarter. Bedel Financial Consulting Inc. now owns 502 shares of the medical technology company’s stock valued at $57,000 after buying an additional 151 shares during the period. O Shaughnessy Asset Management LLC increased its stake in shares of Hill-Rom by 14.3% in the second quarter. O Shaughnessy Asset Management LLC now owns 1,270 shares of the medical technology company’s stock valued at $144,000 after buying an additional 159 shares during the period. Finally, Howe & Rusling Inc. boosted its position in shares of Hill-Rom by 8.0% during the 1st quarter. Howe & Rusling Inc. now owns 2,922 shares of the medical technology company’s stock valued at $323,000 after purchasing an additional 216 shares in the last quarter. 84.11% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:HRC opened at $151.49 on Thursday. Hill-Rom Holdings, Inc. has a 52-week low of $86.51 and a 52-week high of $152.37. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.03 and a current ratio of 1.38. The business’s 50 day simple moving average is $144.15 and its two-hundred day simple moving average is $124.98. The firm has a market cap of $9.97 billion, a P/E ratio of 42.67 and a beta of 0.60.

Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, July 30th. The medical technology company reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.03. Hill-Rom had a return on equity of 21.74% and a net margin of 8.12%. The company had revenue of $717.70 million for the quarter, compared to analyst estimates of $708.33 million. During the same quarter last year, the company earned $1.95 earnings per share. The company’s revenue for the quarter was down 6.5% on a year-over-year basis. On average, equities analysts forecast that Hill-Rom Holdings, Inc. will post 6.11 earnings per share for the current fiscal year.

In related news, SVP Mary Kay Ladone sold 9,056 shares of the stock in a transaction that occurred on Wednesday, July 28th. The stock was sold at an average price of $127.62, for a total transaction of $1,155,726.72. Following the completion of the sale, the senior vice president now directly owns 2,698 shares of the company’s stock, valued at $344,318.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.69% of the stock is owned by company insiders.

Several equities research analysts recently commented on the company. KeyCorp lowered Hill-Rom from an “overweight” rating to a “sector weight” rating in a research report on Wednesday, September 8th. Bank of America lowered Hill-Rom from a “buy” rating to a “neutral” rating and set a $130.00 target price on the stock. in a research report on Tuesday, August 10th. Morgan Stanley lowered Hill-Rom from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $148.00 to $156.00 in a report on Sunday, September 19th. Finally, Robert W. Baird lowered Hill-Rom from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $150.00 to $156.00 in a report on Friday, September 3rd. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Hill-Rom currently has a consensus rating of “Hold” and a consensus target price of $141.80.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions.

Read More: What is the definition of market timing?

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.